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TM6SF2 rs58542926 variant affects postprandial lipoprotein 
metabolism and glucose homeostasis in NAFLD. 
 A clue to the opposite impact of TM6SF2 variant on liver and cardio-metabolic disease? 
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ABBREVIATIONS: AI: adaptation index; AUC: area under the curve; BIA: 
bioelectrical impedance analysis; BMI: body mass index; CGI: CP-genic index; Chol: 
cholesterol;  CK-18: cytokeratin-18;  CVD: cardiovascular disease;  DI: disposition 
index; EPIC: European Prospective Investigation into Cancer and Nutrition;  FFA: free 
fatty acids;  FIVGTT: frequently-sampled intravenous glucose tolerance test; HII: hepatic 
iron index; IGI:   insulinogenic index; IAUC: incremental AUC;  LIC: liver iron 
concentration; NAFLD: nonalcoholic fatty liver disease; NASH:  nonalcoholic 
steatohepatitis; NT: nitrotyrosine OFTT: oral fat load test; OGIS: oral glucose insulin 
sensitivity index; OGTT: oral glucose tolerance test; oxLDL: oxidized LDLs; SNP: 
single nucleotide polymorphism; TAS: total antioxidant status;  Tg: triglyceride;  TNF:  
tumor necrosis factor; TRLP: triglyceride-rich lipoproteins; VLDL: very low density 
lipoprotein 
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ABSTRACT. 
Mechanisms underlying the opposite effects of TM6SF2  rs58542926 C>T polymorphism  
on liver injury and cardio-metabolic risk   in NAFLD are unclear. We assessed the impact 
of  this polymorphism on postprandial  lipoprotein metabolism, glucose homeostasis, and 
nutrient oxidation in NAFLD.  
Sixty nonobese, nondiabetic, normolipidemic biopsy-proven NAFLD patients  and 60 
matched controls genotyped for TM6SF2 C>T polymorphism underwent: indirect 
calorimetry, an oral fat tolerance test with measurement of plasma lipoprotein 
subfractions,  adipokines, incretin GIP, and an OGTT with Minimal Model analysis of  
glucose homeostasis.  
TM6SF2  T-allele was associated with higher hepatic and adipose insulin resistance, with 
impaired pancreatic ß-cell function and incretin effect and with higher muscle insulin 
sensitivity and whole-body fat oxidation rate.   
Compared with TM6SF2 C-allele,  T-allele  entailed lower postprandial lipemia and 
nefaemia, a less atherogenic lipoprotein profile,  a postprandial cholesterol redistribution 
from smaller, atherogenic lipoprotein subfractions to larger intestinal and hepatic VLDL1 
subfration. Postprandial plasma  VLDL1-cholesterol response independently  predicted 
the severity of liver histology. 
In conclusion,  TM6SF2  C>T polymorphism affects nutrient oxidation, glucose 
homeostasis, and postprandial  lipoprotein, adipokine and GIP responses to fat ingestion, 
independently of fasting values. These differences may contribute to the  dual and 
opposite effect of this polymorphism on liver injury and cardio-metabolic risk  in 
NAFLD. 
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INTRODUCTION 
Nonalcoholic fatty liver disease (NAFLD) confers an increased risk of liver-related 
complications (largely limited to its progressive form, non-alcoholic steatohepatitis, 
NASH), of  type 2 diabetes (T2DM), and of cardiovascular disease (CVD)[1,2]. The wide 
inter-individual variability in the risk of hepatic and extra-hepatic complications in 
NAFLD may reflect the interplay between genetic and environmental factors. While in 
the general population an association between the type and amount of dietary fat and the 
development of obesity,  CVD and T2DM has been demonstrated [3],data linking dietary 
fat to the presence and severity of NAFLD  are controversial [4,5].We hypothesized a 
genetically determined  susceptibility to dietary fat lipotoxicity modulates liver injury and 
cardio-metabolic risk in NAFLD. 
The single nucleotide polymorphism (SNP)  rs58542926 C>T in the Transmembrane 6 
superfamily member 2 gene (TM6SF2) has been recently linked to  the severity of 
NAFLD in genome-wide association studies (GWAS) [6,7]: TM6SF2 T-allele,  encoding 
the E167K aminoacidic substitution, results in reduced transcript levels of its product 
protein, which is expressed in humans in the liver, intestine, adipose tissue and pancreatic 
-cells and has unclear biological function[8,9].  
TM6SF2  C>T variant has been linked to a reduced LDL-cholesterol level and 
cardiovascular risk and to an increased risk of  type 2 diabetes [10,11]. Mechanisms 
connecting TM6SF2 C>T polymorphism to liver injury and cardio-metabolic risk are 
unclear. The  impaired  hepatic VLDL secretion associated with TM6SF2 T-allele[8,9] 
may not be the main mechanism mediating NASH, as enhanced lipid storage into neutral 
triglycerides protects against liver injury[12]. Furthermore, the reduced CVD risk 
associated with TM6SF2 T-allele is not fully explained by  lower fasting cholesterol  
levels [13]. Postprandial lipemia is an emerging cardio-metabolic  risk factor, 
independently of fasting lipid levels[14], and dietary fat lipotoxicity has been implicated 
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in liver injury in NASH[3,4,5]: Hypothesizing   dietary fat  lipotoxicity may mediate the 
impact of TM6SF2 on  liver disease and cardio-metabolic risk in NAFLD, we  assessed 
the effect of TM6SF2 C>T variant  on postprandial lipoprotein metabolism and on 
glucose homeostasis in biopsy-proven NAFLD patients and healthy controls.  
 
METHODS  
Participants. There are no data on the impact of TM6SF2 C>T variant  on postprandial 
lipoprotein metabolism and glucose homeostasis. Based on available data on the impact 
of  TM6SF2 C>T variant  on fasting lipid levels [6,7,8,10] and on the impact of NAFLD 
on lipoprotein and glucose metabolism [12,15],  considering a type I error of 0.05 and a 
type II error of 0.20: at least 18 T-allele carriers per arm   were needed to detect a 
significant difference in parameters related to lipoprotein metabolism (IAUC triglyceride 
and LDL-C) and glucose homeostasis (whole-body and tissue insulin sensitivity, β-cell 
function) within different TM6SF2 genotypes in NAFLD patients.  
As obesity, dyslipidemia and diabetes may modify the effect of TM6SF2 C>T variant on 
glucose/lipid metabolism, on adipokines and on liver disease,  subjects with obesity(BMI 
≥30 kg/m2), diabetes(fasting plasma glucose 126 mg/dl or plasma glucose 200 mg/dL 
at +2h on OGTT or antidiabetic drugs), overt dyslipidaemia(fasting serum cholesterol ≥ 
200 mg/dL or plasma triglyceride ≥ 200 mg/dL) or clinical signs/symptoms of CVD were 
excluded. 
Sixty nonobese nondiabetic normolipidemic biopsy-proven NAFLD patients referred to 
two Hepato-Metabolic Clinics were included (criteria for diagnosis of NAFLD are 
detailed in Supplementary Online Appendix). Each pathological feature of liver biopsy 
was read by a single pathologist (RP) blinded to the patient clinical-biochemical 
characteristics and scored according to the NASH Clinical Research Network criteria; 
NASH was defined according to current recommendations[1]. 
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Sixty randomly identified healthy controls,  i.e. nondiabetic nonobese normolipidemic  
individuals without evidence of CVD, randomly selected from a population-based cohort 
study, matched for TM6SF2 C>T genotype, age, gender, BMI, and  waist circumference 
were included[12]. Criteria to rule out NAFLD in controls are detailed in Supplementary 
Online Appendix. 
Patients and controls were characterized for  lifestyle habits, routine biochemistry, 
adipokine profile, markers of inflammation and endothelial dysfunction, as detailed 
below.  Homeostasis model assessment of insulin resistance (HOMA-IR) index was 
calculated as the product of the fasting glucose and insulin concentration divided by 
22.5[16]. 
Participants gave their consent to the study, which was conducted according to the 
Helsinki Declaration and was approved by the Institutional Review Board of San 
Giovanni Battista Hospital, Turin, Italy 
Genetic analyses.   
Genotyping for TM6SF2 rs58542926 C/T SNP utilized the real-time allele discrimination 
method, using TaqMan Allelic Discrimination Assay (Applied Biosystems, Foster city, 
CA). The TaqMan genotyping reaction was run on an 7300HT Fast Real-Time PCR 
(Applied Biosystem). 
We also genotyped our population for the PNPLA3 SNP rs738409 C/G and for apoE 
genotype, which have been previously linked to both NAFLD and lipid metabolism[17], 
to assess their interference with outcome variables (detailed in Supplementary Online 
Appendix). 
Dietary and physical activity record.  
Participants filled in the validated European Prospective Investigation into Cancer and 
Nutrition (EPIC) 7-day alimentary questionnaire, and the  Minnesota-Leisure-Time-
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Physical-Activity questionnaire, and data were analyzed as described in Supplementary 
Online Appendix.  
 
Anthropometry.   
Percent body fat was estimated by the bioelectrical impedance analysis (BIA) method 
(TBF-202, Tanita, Tokyo, Japan), closely correlating with dual X ray absorption[18]. 
Abdominal visceral fat area (cm
2
) was estimated using Stanforth equations, validated 
against computed tomography in black and white Caucasians[19]. 
 
Indirect calorimetry and substrate oxidation rates.  
After an overnight (12 h) fast, participants underwent indirect calorimetry measurement 
of oxygen consumption (VO2) and carbon dioxide production (VCO2) using an open 
circuit indirect calorimeter with a ventilated-hood system (Deltatrac™ II, Datex 
Instrumentarium Corp., Helsinki, Finland)(see Supplementary Online Appendix). 
Whole-body respiratory quotient (RQ) and non-proteic RQ(npRQ) wERE calculated as 
VCO2/VO2. Resting energy expenditure (REE), and whole-body CHO oxidation 
(CHOox) and fat oxidation rates (Fatox) were calculated from VO2 and VCO2 by using 
stoichiometric equations and appropriate energy equivalents[20].  REE and substrate 
oxidation rates were corrected for fat-free mass(FFM). 
Markers of cardiovascular risk/endothelial dysfunction and adipokines.  
Serum C-reactive protein (CRP), soluble adhesion molecules E-selectin and intercellular 
adhesion molecule (ICAM)-1 were measured as validated markers of  CVD risk,  
endothelial dysfunction, and subclinical atherosclerosis[21,22](detailed in Supplementary 
Online Appendix). Circulating  adipokines adiponectin, tumor necrosis factor(TNF)-, 
resistin and leptin were measured by immunoenzymatic methods (see Supplementary 
Online Appendix).  
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Oral glucose tolerance test (OGTT)-derived indexes of glucose homeostasis. 
Participants underwent a standard 75-g OGTT and  indexes of glucose homeostasis were 
calculated (detailed in Supplementary Online Appendix). Whole body oral glucose insulin 
sensitivity index (OGIS),  and hepatic and muscle insulin resistance indexes were 
calculated  as previously proposed and validated against clamp in nondiabetic 
subjects[23, 24].  
Adipose tissue insulin resistance (adipo-IR) index was calculated as fasting non-esterified  
fatty acids (NEFA) x fasting insulin[15]. 
The Minimal Model technique was used to calculate  the following  indexes of β-cell 
function: the insulinogenic index (IGI) and the CP-genic index (CGI) and the 2 integrated 
indexes of -cell function disposition index (DI) and adaptation index (AI), which relate 
-cell insulin secretion to insulin resistance. DI and AI were previously validated against 
frequently-sampled intravenous glucose tolerance test (FIVGTT) in NAFLD   and in 
nondiabetic subjects[21,25] and reliably predict T2DM development[26]. 
Incretin effect. To assess if differences in -cell function  were related to a reduced 
incretin stimulatory effect on -cell, a FIVGTT was performed and the incretin effect, 
i.e., the effectiveness of ingested glucose in stimulating -cell insulin secretion  compared 
to intravenous. glucose, was assessed (see Supplementary online Appendix).  
 
Oral fat tolerance test (OFTT).  
 
Participants underwent a 10-hour oral fat tolerance test(OFTT)[14] with measurement of 
the following parameters (methods detailed in Supplementary Online Appendix): 
1)plasma total cholesterol (Chol),  triglyceride (Tg),  NEFA and HDL-C   
2)triglyceride-rich lipoproteins (TRLP) subfractions and LDL: TRLP were isolated 
through preparative ultracentrifugation and their total Tg and Chol content were 
subsequently measured as described in Supplementary Online Appendix.  
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Two VLDL subfractions with decreasing Sf values (VLDL1: Sf>100; VLDL2: Sf =20-
100) were separated and their Chol and Tg content was determined (see Supplementary 
Online Appendix). 
VLDL apoB48 and apoB100 were separated by sodium dodecyl sulfate (SDS)-
polyacrylamide gel electrophoresis using 3,9% gel (detailed in Supplementary Online 
Appendix). 
LDL cholesterol content was measured with a standardised homogeneous enzymatic 
colorimetric method in order to avoid triglycerides effects on LDL determination 
(Sentinel) (see Supplementary Online Appendix). 
  
3)lipid-induced oxidative stress: oxidized low-density lipoproteins (oxLDLs). LDL 
conjugated dienes, validated markers of oxLDLs, were determined by capillary 
electrophoresis(detailed in Supplementary Online Appendix). 
4) Glucose-dependent insulinotropic polypeptide (GIP), adiponectin and resistin.  
GIP is  an emerging  modulator of lipid metabolism independently of its incretin effect on 
pancreatic -cell function. Dietary fat is the most potent stimulator of GIP secretion [27], 
and TM6SF2 protein is   expressed by human  intestinal cells[12]; furthermore,  acute and 
chronic administration of GIP, but not of glucagon-like peptide(GLP)-1, reduces fat 
oxidation and energy expenditure[28],  induces adipocyte dysfunction and  
proinflammatory adipokine secretion[29], and promotes  development of obesity-
associated metabolic disorders[30], including NAFLD, which were all reversed by  GIP 
antagonists[28].  
Plasma GIP, as well as  resistin and  adiponectin,  which have been linked to both liver 
disease severity and lipoprotein metabolism in NAFLD, were measured as detailed in 
Supplementary Online Appendix. 
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Statistical analysis  
Differences across groups were analyzed by ANOVA followed by Bonferroni correction, 
when variables were normally distributed; otherwise the Kruskal-Wallis test, followed by 
the post hoc Dunn test, was used. Normality was evaluated by Shapiro-Wilk test. Fisher 
or chi-square test were used to compare categorical variables, as appropriate.  Hardy–
Weinberg equilibrium was assessed using 2 test.  
To adjust for multiple comparison testing, the Benjamini-Hochberg False Discovery Rate 
correction was applied to  raw p-values in all comparisons; significance was set at an 
adjusted p-value threshold of 0.05[31]. 
The area under the curve(AUC) and  incremental AUC(IAUC) of parameters measured 
during the OFTT and the OGTT were computed by the trapezoid method.  
Due to the low prevalence of TM6SF2 TT homozygotes and to the overlapping clinical 
characteristics with  heterozygous CT carriers,  TM6SF2 TT carriers were combined with 
CT  heterozygotes for group comparisons.  
 Differences were considered statistically significant at p<0.05. 
Analysis of dietary, anthropometric and metabolic parameters and of genetic 
polymorphisms was made using Spearman correlation test to assess correlation among 
different variables.  
Based on  available evidence [6,7,8,10], TM6SF2 C>T variant  was modelled as a 
dominant model of inheritance, that is, quantitative predictor variables reflecting the 
number of risk alleles (0, 1, or 2). 
When a relation was found on univariate analysis, multivariate logistic regression was 
used to identify independent predictors of  selected outcome variables of interest, namely:  
-for liver histology: the presence of NASH and of advanced (stage 3) fibrosis 
- for CVD risk:  serum CRP and endothelial adhesion molecules E-selectin and ICAM-1;  
-for whole-body nutrient oxidation rates: CHOox and fatox. 
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-for glucose homeostasis: OGTT-derived parameters of whole-body/tissue insulin 
resistance and of β-cell function;   
-for postprandial lipid metabolism: the  IAUC of triglyceride, LDL-C, oxLDL and of of 
main triglyceride-rich lipoprotein subfractions. 
For this analysis, continuous variables were divided into quartiles and independent 
predictors of the highest quartile of outcome variable were asesssed, after after log 
transformation of skewed data.  The independent predictors were those variables found to 
be related to the outcome variables on univariate analysis. 
Data were expressed as mean ± SEM,  unless otherwise specified. (STATISTICA 
software, 5.1, Statsoft Italia, Padua, Italy) 
 
RESULTS. 
Subjects characteristics  
Main features of patients and controls grouped according to  TM6SF2 C>T genotype are 
reported in Table 1.  
In study participants, the prevalence TM6SF2 CC homozygotes was 64%, of CT 
heterogygotes was 34%, of TT carriers was 2%; 
The distribution of TM6SF2 CT genotype was in Hardy-Weinberg equilibrium(6, 7, 8). 
NAFLD as a group had higher HOMA, serum CRP and endothelial adhesion molecules 
E-selectin and ICAM-1 and lower HDL-C and adiponectin than controls. Within NAFLD 
patients and controls, TM6SF2 CT/TT carriers showed lower serum CRP and endothelial 
adhesion molecules than TM6SF2 CC genotype carriers (Table 1). 
Among NAFLD patients, 42% had NASH and 16% had advanced fibrosis. TM6SF2 T-
allele carriers had  more severe  liver histology than their counterpart genotype (Table 1). 
Alimentary record.  
There was no difference in daily total energy, macro- and micro-nutrient, types of fat and  
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 antioxidant vitamin intake between patients with NAFLD and controls and among  
different TM6SF2  genotypes (not shown).  
Indirect calorimetry. 
While TM6SF2 C>T variant did not affect REE, the proportion of energy derived from 
fat and CHO oxidation differed between TM6SF2  genotypes:  TM6SF2 T-allele carriers 
had  lower RQ and npRQ, indicating they  oxidize more fat and less CHO that CC 
homozygotes(Table 1). 
 
OGTT-derived indexes of glucose homeostasis 
The time course of plasma glucose and serum insulin during the OGTT is reported in  
Figure S1. In patients and controls,  TM6SF2 T-allele carriers showed higher hepatic and 
adipose insulin resistance but enhanced muscle insulin sensitivity than CC homozygotes 
TM6SF2 CT/TT genotype displayed also  impaired  pancreatic β-cell function and 
incretin effect than CC homozygotes(Table 2). 
 
Oral fat tolerance test.  
Within patients and controls, TM6SF2 CT/TT genotype showed lower postprandial Tg, 
VLDL1-Tg,  NEFA and oxLDL responses, a higher increase in postprandial cholesterol 
content in VLDL1 and VLDL2 subfractions of intestinal and hepatic origin, and a slight 
but statistically significant  postprandial LDL-C decrease as compared with TM6SF2 CC 
genotype (Table 3, Figure 1 panel A-D, Supplementary  Figure  S2).   
TM6SF2 CT/TT genotype showed also lower postprandial GIP and higher  resistin 
responses than homozygous CC carriers (Table 3, Figure 1 panel F-G). 
 
 
Independent predictors of outcome variables on multiple logistic regression analysis  
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Liver histology: NASH was independently predicted by  by IAUC VLDL1-Ch 
(OR=1.60, 95% CI: 1.1-2.2, p=0.009), while  advanced (stage 3) fibrosis was predicted 
by IAUC adiponectin (OR=1.41, 95%CI: 1.1-2.0, p=0.021 ) and IAUC VLDL1-
Ch(OR=1.53, 95%CI: 1.1-2.2, p=0.010). 
Circulating markers of CVD risk:  IAUC triglyceride and IAUC oxLDLs  
independently predicted C-reactive protein (OR=1.51, 95%CI: 1.05-2.65, p=0.006 and 
β=1.48, 95%CI: 1.08-2.54, p=0.005, respectively),  E-selectin (OR=1.56, 95%CI: 1.11-
2.61, p=0.002 and OR=1.54, 95%CI: 1.19-2.63, p=0.0009, respectively), and ICAM-
1(OR=1.54, 95%CI: 1.18-2.78, p=0.009 and OR=1.52, 95%CI: 1.07-2.77, p=0.010, 
respectively). 
Whole-body Fatox was independently predicted by IAUC adiponectin (OR=1.49, 95%CI: 
1.14-2.59, p=0.002).  and IAUC GIP (β=0.49, 95%CI: 0.18-0.88, p=0.012).  
The independent determinants of OGTT-related glucose homeostasis parameters and of 
posptrandial lipoprotein and adipokine responses during oral tat tolerance test  are 
reported in Table 4. 
 
DISCUSSION 
The main findings of our study are the following: 
1)TM6SF2 C>T variant modulates postprandial lipid metabolism: despite similar fasting 
lipid levels,  TM6SF2 CT/TT carriers show   lower postprandial triglyceride, NEFA and 
oxLDL responses, higher HDL-C levels, and a  cholesterol redistribution   from LDL to 
larger intestinal and hepatic TRLPs subfractions. TM6SF2 T-allele carriers have also  
higher incretin GIP and resistin elevations after  fat ingestion.  
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2)Postprandial plasma VLDL1-Ch elevation independently predicts the severity of liver 
histology in NAFLD, while triglyceride and oxDLD responses were independently 
associated with markers of CVD risk. 
3)TM6SF2 C>T variant affects  tissue  insulin resistance, pancreatic ß-cell function, and 
whole-body substrate oxidation rate, the latter  possibly through modulation of GIP 
response to dietary fat.  
Postprandial lipemia is an  independent cardio-metabolic risk   factor in the Western 
world and, consistently,  individuals spend most of the day in the postprandial phase 
rather than in fasting conditions[14]. The effect of TM6SF2 variant on dietary fat 
metabolism may  contribute to the dual and opposite effect of this SNP on liver disease 
severity and on CVD risk in NAFLD[32]: following fat ingestion, TM6SF2 T-allele 
carriers showed a shift in cholesterol content from LDL to larger intestinal and hepatic 
VLDL subfractions, which are preferentially taken-up by  liver cells and adipocytes 
through the low-density lipoprotein receptor-related protein (LRP)[33, 34] and the 
VLDL-receptor(VLDLR)[35], thereby  triggering hepatocyte apoptosis and adipocyte 
dysfunction[33,34,35]. The independent association of postprandial VLDL-Ch response 
with liver histology is consistent with recent data, demonstrating  an important role for 
TRLP uptake  in promoting high fat-induced liver injury[36] and linking cholesterol 
concentration in VLDL subclasses to hepatic cholesterol content, inflammation, and 
fibrosis[37]. 
These findings suggest  TM6SF2 T-allele-associated  postprandial lipoprotein pattern 
may divert toxic cholesterol away from the vessel walls into the liver and adipose tissue, 
enhancing liver injury and adipose dysfunction and protecting from CVD.  
The independent association of CVD risk markers with postprandial triglyceride and 
oxLDL responses, which were lower in TM6SF2 T-allele carriers,  is also consistent with 
an important role for postprandial lipoprotein metabolism in mediating the 
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cardioprotective role of T-allele observed in large epidemiological studies[7,10] 
The lower postprandial triglyceride response  in   TM6SF2 T-allele carriers may be due to 
lower fat  absorption,  or greater chylomicron clearance. The lower increase in NEFA is 
not consistent with greater chylomicron clearance, which would have increased plasma 
NEFA through spillover. Additionally  a recent report showed TM6SF2 T-allele impairs 
triglyceride processing and secretion in enterocytes[38], confirming a reduced 
triglyceride absorption may underlie the lower postprandial lipemia observed in TM6SF2 
T-allele carriers. 
 
If confirmed by larger studies, these findings may have therapeutic implications, as 
cholesterol-lowering interventions may reduce  cholesterol hepatotoxicity in TM6SF2 T-
allele carriers, irrespective of fasting cholesterol levels. 
We also evaluated the impact of TM6SF2 SNP on glucose homeostasis, as both NAFLD 
and TM6SF2 C>T variant have been associated with an increased risk of type 2 
diabetes[2,11] . TM6SF2 gene variant affected tissue insulin sensitivity and pancreatic β-
cell function: TM6SF2 T-allele was associated with  an impaired incretin effect and ß-cell 
function, possibly  via a reduced incretin secretion or  action on ß-cells, which express 
TM6SF2 protein[13]. These findings may help select NAFLD carriers of TM6SF2 at-risk 
genotype, who are also at higher risk of T2DM for targeted preventive interventions 
improving β-cell dysfunction, including incretin mimetics. 
An intriguing finding was the impact of TM6SF2 SNP on muscle insulin sensitivity and 
whole-body fat oxidation rates, both effects related to  postprandial adiponectin and  GIP 
responses to fat (Table  4).   
Consistent with our data,   adiponectin stimulates muscle fat oxidation and insulin 
sensitivity, while GIP potently reduces energy expenditure and fat oxidation[39]. The link 
between TM6SF2 and  incretins  and the role of GIP antagonism to enahnce fat oxidation 
and insulin sensitivity warrant future investigation. In the meantime, it should be noted  
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that  GIP increase  induced by dipeptidyl peptidase-IV (DDP-IV) inhibitors, currently 
evaluated in NAFLD, may  attenuate the benefits of glucagon-like peptide(GLP)1 
elevation[40].  
In conclusion,  a maladaptive response to a chronic, daily, repetitive metabolic challenge 
like fat ingestion may link TM6SF2 C>T variant to liver injury and cardio-metabolic 
disease in NAFLD. Future research should unravel  underlying  molecular pathways in 
different tissues and organs, allowing  therapeutic interventions tailored to individual risk 
profile and mechanism of injury[41,42,43].  
Strengths of our study are the careful selection and thorough characterization of 
participants.  Limitations are the small number of subjects and the cross-sectional design, 
which prevents any causal inference between TM6SF2 variant and the abnormalities in 
lipid and glucose metabolism and requires confirmation by larger follow-up studies.   
A further caveat is that we did not measure directly hepatic and muscle insulin sensitivity 
but rather estimated them from the time course of glucose and insulin during the OGTT. 
This method  assumes a similar intestinal glucose absorption rate across TM6SF2 
genotypes, as a faster glucose absorption rate in TM6SF2 T-allele carriers would cause a 
steeper increase and an earlier peak and fall in plasma glucose regardless of any actual 
differences in tissue insulin sensitivity: however, the visual inspection of plasma glucose 
curve during the OGTT (Supplementary Figure S1) shows a similar slope in the  0’-30’ 
ascending limb of the curve across TM6SF2 genotypes and the same peak  time (+60’), 
making differences in glucose absorption very unlikely to occur. 
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Table 1.Main clinical, biochemical and histological parameters of biopsy-proven 
NAFLD patients and controls grouped according to TM6SF2  C/T polymorphism 
(n=120). 
 Controls NAFLD 
 TCM6F2 
CC 
(n=40) 
 
TCM6F2 
CT/TT 
(n=20) 
P 
 
TM6SF2 
CC 
(n=40) 
 
TM6SF2 
CT/TT 
(n=20) 
P 
Age (years) 42±2 42±2 0.851 42±2 40±2 0.851 
 Sex (%males) 68 65 0.693 68 65 0.693 
 BMI (kg/m2) 25.6±0.5 25.9±0.6 0.731 25.6±0.5 25.8±0.6 0.690 
Fat mass(%) 22±2 22±2 0.872 23±2 22±2 0.232 
Waist (cm) 89±3 90±4 0.482 89±2 90±2 0.426 
WHR 0.91±0.02 0.91±0.03 0.756 0.92±0.03 0.92±0.03 0.731 
 AVF(cm2) 99±5 103±6 0.731 101±5 97±6 0.832 
 Smokers (%) 31 30 0.410 33 31 0.390 
Systolic BP (mmHg) 
 
 
118±3 123±2 0.291 121±2 127±2 0.280 
Diastolic BP (mmHg) 
 
80±2 84±2 0.130 83±2 87±5 0.122 
AST (U/L) 15±1 16±2 0.591 32±2 41±4‡ 0.131 
ALT (U/L) 19±2 2312 0.678 70±5 88±6‡ 0.111 
GGT (U/L) 35±5 43±4 0.702 89±16 108±18 0.089 
Tg (mg/dL)  
 
98±211 86±10 0.879 94±17 85±13 0.561 
Total C (mg/dL)  179±9 168±7 0.311 187±11 173±12 0.132 
HDL-C (mg/dL)  
 
 
54±2 55±2 0.210 52±2§ 54±2§ 0.118 
LDL-C (mg/dL)  103±6 94±6 0.131 107±5 95±10 0.210 
Glucose(mg/dL) 99±3 90±3 0.394 100±10 90±7 0.273 
  Insulin (U/mL) 7.2 ±1.8 6.3±1.2 0.569 13.7±3.8 15.9±6.4 0.543 
HOMA-IR 1.9±0.9 1.3±0.8 0.298 3.55±1.1  2.9±0.90 0.220 
METS(h/week) 21.2±1.0 22.2±1.7 0.413 22.7±1.5 21.9±1.4 0.639 
RQ 0.81±0.01 0.77±0.01 0.001 0.81±0.01 0.78±0.01 0.003 
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npRQ 0.81±0.02 0.76±0.01 0.001 0.82±0.01 0.77±0.01 0.0009 
REE(kcal/24h/kg/FFM) 29.5±1.8 29.9±2.0 0.711 29.7±1.5 28.4±1.7 0.302 
Fatox 
(mg/kg/FFM/min) 
1.23±0.05 1.54±0.05 0.0009 1.22±0.06 1.50±0.08 0.002 
CHOox 
(mg/kg/FFM/min) 
2.00±0.10 1.42±0.11 0.001 1.99±0.11 1.45±0.10 0.002 
Hs-CRP(mg/L) 1.90.2 1.10.4 0.009 3.102† 2.002§ 0.001 
E-selectin (ng/mL) 31.1±3.1 20.1±4.6 0.010 51.3±4.8† 28.9±3.1§ 0.002 
ICAM-1(ng/mL) 239.1±4.6 191.8±5.3 0.028 285.1±5.2† 228.6±6.0§ 0.009 
TNF- (pg/mL) 1.20±0.18 1.08±0.21 0.512 1.18±0.17 0.99±0.25 0.471 
Leptin (pg/mL) 1830±399 1793±224 0.430 1746±275 1914±201 0.711 
ApoE  Genotype(%) 
2-3 
3-3 
3-4 
 
16 
66 
18 
 
14 
67 
19 
 
0.573 
0.312 
0.690 
 
14 
67 
19 
 
16 
67 
17 
 
0.689 
0.911 
0.892 
PNPLA3 (%) 
CC 
CG 
GG 
 
41 
41 
8 
 
55 
33 
12 
 
0.671 
0.312 
0.218 
 
41 
41 
8 
 
55 
33 
12 
 
0.671 
0.312 
0.218 
abdominal  obesity (% ) 17 20 0.691 17 20 0.691 
IGR(%) 19 8 0.231 21 10 0.289 
Hypertension(%) 30 27 0.379 51 49 0.592 
Low HDL-C(%) 13 9 0.398 16 9 0.401 
High Tg(%) 13 9 0.412 14 8 0.379 
Met sy (%) 
 
37 29 0.311 40§ 31§ 0.297 
Steatosis(% hep.) - - - 253 324 0.168 
NAFLD activity score   - 2.00.2 4.00.3 0.0001 
Fibrosis stage - - - 0.20.1 1.00.2 0.0001 
NASH(%) - - - 31 61 0.045 
 
* p<0.05 vs. controls  
† p<0.01 vs. controls 
§  p<0.05 vs. controls bearing the same genotype   
‡ p<0.01 vs.  controls bearing the same genotype   
¶  p<0.05 vs. controls bearing the counterpart genotype   
# p<0.01 vs.  controls bearing the counterpart genotype   
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Abbreviations. AVF: abdominal visceral fat area; BP: blood pressure; total C: total 
cholesterol; Fatox: fat oxidation rates: FFM: tat-free mass; hs-CRP: highly sensitive C-
reactive protein; CHO: carbohydrates; RQ:  respiratory quotient; npRQ: nonproteic 
respiratory quotient; REE: resting energy expenditure; WHR: waist-on-hip ratio; Tg: 
triglyceride; IGR: impaired glucose regulation; HOMA-IR: homeostasis model 
assessment of insulin resistance; ICAM: intercellular adhesion molecule; METS: 
Metabolic equivalent of activity;  Met sy: metabolic syndrome according to the joint 
statement of AHA, IDF and NHLBI;  
MTP: microsomal triglyceride transfer protein; SREBF: sterol regulatory element-
binding factor; 
Met Sy: metabolic syndrome according to the joint statement of AHA, IDF and NHLBI, 
requires the presence of  ≥3 of the following criteria: 
-abdominal obesity: waist circumference≥102 cm(males) and ≥88 cm(females) 
-high triglycerides: ≥150 mg/dL (1.7 mmol/L) or on drug treatment for elevated 
triglycerides 
-low HDL-C:  <40 mg/dL (1.0 mmol/L) (males) or <50 mg/dL (1.3 mmol/L) (females) or 
on drug treatment for reduced HDL-C 
-hypertension: systolic BP≥130 and/or diastolic BP≥85 mm Hg or on drug treatment 
-high fasting plasma glucose (FPG): FPG ≥100 mg/dL (5.6 mmol/L) or on drug treatment 
for elevated glucose.  
 
 
 
 
 28 
 
                                                                                                                                                 
Table 2. OGTT-derived  Indexes of Glucose Homeostasis in patients with biopsy-proven 
NAFLD and controls,   grouped according to TM6SF2 rs58542926 C/T genotype 
(n=120). 
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* p<0.05 vs. controls  
† p<0.01 vs. controls 
§  p<0.05 vs. controls bearing the same genotype   
‡ p<0.01 vs.  controls bearing the same genotype   
¶  p<0.05 vs. controls bearing the counterpart genotype   
# p<0.01 vs.  controls bearing the counterpart genotype   
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Data are presented as mean  SEM, unless otherwise specified.  
Abbreviations: OGIS: oral glucse insulin sensitivity index; IR: insulin resistance;  
IS: insulin sensitivity; IGI: insulinogenic index; CGI: Cp-genic index;   
DI: Disposition Index; AI: Adaptation Index 
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Table 3. Oral fat tolerance test parameters in patients with NAFLD and controls grouped 
according to TCM6F2 rs58542926 C/T genotype (n=120). 
 Controls NAFLD 
Parameter TCM6F2 
CC 
(n=40) 
TCM6F2 
CT/TT 
(n=20) 
 
 
P 
 
TCM6F2 
CC 
(n=40) 
 
 
TCM6F2 
CT/TT 
(n=20) 
P 
Fasting Tg(mg/dL) 9811 8610 0.812 9415 8518 0.513 
IAUC Tg (mg/dL x hr) 14112 7910 0.001 52521† 29720† 0.00001 
Fasting NEFA (mmol/L) 0.350.23 0.470.28 0.712 0.500.29 0.630.31 0.711 
IAUC NEFA (mmol/L x hr) 1.930.27 0.820.15 0.00009 5.240.22† 2.310.28§ 0.0001 
Fasting VLDL1-Tg (mg/dL) 429 4010 0.812 5212 3610 0.201 
IAUC VLDL1-Tg (mg/dL x hr) 40829 12314 0.0001 92237† 49731§ 0.00002 
Fasting VLDL2-Tg (mg/dL) 307 317 0.813 368 429 0.312 
IAUC VLDL2-Tg (mg/dL x hr) 5610 8913 0.301 13714 13119 0.611 
Fasting VLDL1-Ch (mg/dL) 102 122 0.812 144 164 0.713 
IAUC VLDL1-Ch  
(mg/dL x hr) 
414 927 0.00009 979§ 19911† 0.000001 
Fasting VLDL2-Ch (mg/dL) 153 133 0.712 183 204 0.611 
IAUC VLDL2-Ch (mg/dL x hr) 111 322 0.00009 372§ 1084§ 0.000001 
Fasting LDL-C(mg/dL) 103±6 94±6 0.131 107±5 95±10 0.210 
IAUC LDL-C 
(mg/dL x hr) 
-102 -242 0.003 -203 
# § 
-513† 0.0001 
Fasting VLDL1 ApoB48 (mg/dL) 2.10.4 2..00.5 0.812 2.70.9 2.40.9 0.511 
IAUC VLDL1 ApoB48   
 (mg/dL x hr) 
4.50.9 1.90.5 
 
0.0002 8.71.4† 4.31.0§ 
 
0.00001 
Fasting VLDL2 ApoB48 (mg/dL) 1.80.4 1.50.4 0.509 2.30.6 2.10.7 0.421 
IAUC VLDL2 ApoB48  
(mg/dL x hr) 
1.50.3 2.90.5 0.008 1.60.3 5.80.6† 0.0001 
 31 
 
                                                                                                                                                 
Fasting VLDL1ApoB100(mg/dL) 3.71.0 3.51.1 0.712 4.51.6 4.21.7 0.913 
IAUC VLDL1 ApoB100  
(mg/dL xhr) 
10.01.5 3.90.9 
 
0.00009 22.43.5† 11.72.9§ 
 
0.00001 
Fasting VLDL2 ApoB100 
(mg/dL) 
3.70.7 3.20.9 0.802 5.20.9 4.81.1 0.611 
IAUC VLDL2 ApoB100  
(mg/dL x hr) 
4.60.9 8.31.0 0.015 13.81.9† 24.52.6† 0.00001 
Fasting LDL C.D. 
(uA 234 nm/uA 200 nm x 100) 
7.31.6 7.91.8 0.902 7.51.8 7.11.6 0.616 
IAUC LDL C.D. 
(uA 234 nm/uA 200 nm x 100 x 
hr) 
2.10.1 0.80.2 0.0009 15.11.0† 5.21.2* 0.00001 
Fasting HDL-C(mg/dL) 542 552 0.210 522 542 0,212 
IAUC HDL-C (mg/dL x hr) -142 21 0.0001 -564† -182§ 0.00009 
Fasting GIP (pg/mL) 18.8±6.4 16.5±6.1 0.712 22.1±9.5 11.95.2 0.211 
IAUC GIP (pg/mL x hr)  
 
571.9±18.5 266.4±20.1 0.000008 703.9±20.1† 379.624.4 0.000002 
Fasting adiponectin (ng/mL) 8631782 9515812 0.412 6161572 5575650 0.713 
IAUC adiponectin  
(ng/mL x hr) 
11071912 12916926 0.513 1768246 1536494 0.423 
Fasting resistin(ng/mL) 3.40.9 3.11.0 0.912 3.80.9 3.30.9 0.301 
IAUC resistin  (ng/mL x hr) 0.10.1 1.50.3 0.008 2.81.1* 6.411.9† 0.0000001 
 
 Oral fat load parameters of patients with NAFLD and controls according to TM6SF2 
genotype. Data are presented as mean  SEM. Statistically significant P values are 
written in bold characters. 
Abbreviations: IAUC: incremental area under the curve; FFA: free fatty acids; Tg: 
triglyceride;  C.D. : conjugated dienes; Ch: cholesterol; 
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* p<0.05 vs. controls  
† p<0.01 vs. controls 
§  p<0.05 vs. controls bearing the same genotype   
‡ p<0.01 vs.  controls bearing the same genotype   
¶  p<0.05 vs. controls bearing the counterpart genotype   
# p<0.01 vs.  controls bearing the counterpart genotype   
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Table 4. Independent predictors of  parameters related to glucose and lipid metabolism in 
biopsy-proven NAFLD subjects and matched controls  on multivariate logistic regression 
analysis (n=120). 
OGTT-related parameters of glucose homeostasis 
Outcome variable Independent predictor OR (95% CI) P 
OGIS IAUC adiponectin   1.50(1.15-2.51) 0.001 
Hepatic IR IAUC adiponectin 
IAUC resistin 
0.54(0.16-0.86) 
    1.58(1.12-2.63) 
0.001 
0.006 
Adipose tissue IR PNPLA3 
IAUC VLDL1-Ch 
1.52(1.06-2.76) 
1.45(1.05-2.59) 
0.008 
0.002 
Muscle IS IAUC adiponectin 
IAUC GIP 
1.47(1.07-2.46) 
0.49(0.18-0..91) 
0.011 
0.012 
Insulinogenic Index (IGI) TM6SF2 
IAUC adiponectin 
0.49(0.04-0.83)  
1.49(1.04-2.50) 
0.009 
0.004 
Disposition Index (DI) TM6SF2 
IAUC adiponectin 
0.51 (0.16-0.86) 
1.49(1.12-2.55) 
0.001 
0.009 
CP-genic Index (CGI) TM6SF2 
IAUC adiponectin 
0.46 (0.11-0.81) 
 1.68 (1.04-2.50) 
0.001 
0.003 
Adaptation Index (AI) TM6SF2 
IAUC adiponectin 
0.43(0.10-0.70) 
1.79(1.23-2.84) 
0.001 
0.002 
Incretin effect TM6SF2 
IAUC GIP 
0.45(0.11-0.80) 
0.51 (0.16-0.86) 
0.009 
0.007 
Oral fat tolerance test parameters 
Outcome variable Independent predictor OR (95% CI) P 
IAUC triglycerides IAUC adiponectin 
TM6SF2 
0.50(0.14-0.87) 
0.47(0.02-0.82) 
0.003 
0.001 
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IAUC VLDL1-Tg IAUC adiponectin 
TM6SF2 
0.49(0.13-0.84) 
0.43(0.08-0.78) 
0.001 
0.0009 
IAUC VLDL1-Ch TM6SF2 1.69(1.11-2.81) 0.00002 
IAUC VLDL2-Ch TM6SF2 1.55(1.15-2.60) 0.0009 
IAUC VLDL1-apoB100 TM6SF2     0.49(0.13 -0.83) 0.002 
IAUC VLDL2-apoB100 TM6SF2     0.45(0.10-0.81) 0.004 
IAUC VLDL1-apoB48 TM6SF2     0.44(0.02 -0.80) 0.0001 
IAUC VLDL2-apoB48 TM6SF2 0.51(0.06-0.91) 0.023 
IAUC LDL-C TM6SF2 
Fasting LDL-C 
0.50(0.15-0.85) 
1.91(0.36-3.11) 
0.003 
0.0008 
IAUC LDL conjugated dienes IAUC VLDL1-Tg 1.89(1.23-2.95) 0.0001 
IAUC HDL-C IAUC VLDL1-Tg 0.52(0.17-0.87) 0.009 
IAUC GIP TM6SF2 1.88 (1.21-3.01) 0.001 
IAUC resistin TM6SF2 1.58 (1.13-2.92) 0.012 
 
Abbreviations: OGIS: oral glucose insulin sensitivity index; IR: insulin resistance; IS; 
insulin sensitivity; VLDL: very low density lipoprotein; Ch: cholesterol 
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Figure 1. Oral fat load test: postprandial responses in plasma triglycerides (panel A), 
VLDL1 cholesterol (VLDL1-Chol, panel B),  VDLD2 cholesterol (VLDL2-Chol, panel 
C), LDL-C (panel D), oxLDL (panel E), resistin (panel F),  and glucose-dependent 
insulinotropic polypeptide (GIP)(panel G)  . Patients and controls were grouped 
according to TM6SF2 genotype. Data are presented as mean±SEM (N=120). 
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